4.2 Review

Clinical evidence of inflammation driving secondary brain injury: A systematic review

期刊

JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
卷 78, 期 1, 页码 184-191

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TA.0000000000000468

关键词

-

资金

  1. National Heart, Lung, and Blood Institute [5K12HL108974-03]
  2. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL108974] Funding Source: NIH RePORTER

向作者/读者索取更多资源

BACKGROUND: Despite advances in both prevention and treatment, traumatic brain injury (TBI) remains one of the most burdensome diseases; 2% of the US population currently lives with disabilities resulting from TBI. Recent advances in the understanding of inflammation and its impact on the pathophysiology of trauma have increased the interest in inflammation as a possible mediator in TBI outcome. OBJECTIVES: The goal of this systematic review is to address the question: What is the evidence in humans that inflammation is linked to secondary brain injury? As the experimental evidence has been well described elsewhere, this review will focus on the clinical evidence for inflammation as a mechanism of secondary brain injury. DATA SOURCES: Medline database (1996-Week 1 June 2014), Pubmed and Google Scholar databases were queried for relevant studies. STUDY ELIGIBILITY CRITERIA: Studies were eligible if participants were adults and/or children who sustained moderate or severe TBI in the acute phase of injury, published in English. Studies published in the last decade (since 2004) were preferentially included. Trials could be observational or interventional in nature. APPRAISAL AND SYNTHESIS METHODS: To address the quality of the studies retrieved, we applied the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) criteria to assess the limitations of the included studies. RESULTS: Trauma initiates local central nervous system as well as systemic immune activation. Numerous observational studies describe elevation of pro-inflammatory cytokines that are associated with important clinical variables including neurologic outcome and mortality. A small number of clinical trials have included immunomodulating strategies, but no intervention to date has proven effective in improving outcomes after TBI. LIMITATIONS: Inclusion of studies not initially retrieved by the search terms may have biased our results. Additionally, some reports may have been inadvertently excluded due to use of non-search term key words. Conclusions and Implications of Key Findings Clinical evidence of inflammation causing secondary brain injury in humans is gaining momentum. While inflammation is certainly present, it is not clear from the literature at what juncture inflammation becomes maladaptive, promoting secondary injury rather than facilitating repairand identifying patients with maladaptive inflammation (neuro-inflammation, systemic, or both) after TBI remains elusive. Direct agonism/antagonism represents an exciting target for future study. Copyright (c) 2015 Wolters Kluwer Health, Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据